drugset / Trial / NCT03374709

Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia

NCT03374709

Phase 4 Withdrawn University of Colorado, Denver
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the affect Oxtellar XR (Extended Release) has on neurology patients with trigeminal neuralgia (TN), and if it impacts their quality of life.

Timeline

Start
2018-12-14
Primary completion
2018-12-14
Completion
2018-12-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxcarbazepine Small molecule 150 mg

Indications